研報掘金丨國金證券:智飛生物Q2業績快速增長,在研產品管線豐富
國金證券研報指出,HPV疫苗加速放量,智飛生物(300122.SZ)二季度業績快速增長。根據公司公吿, 2021年、 2022年公司代理產品的實際採購金額大幅高於基礎採購金額,未來代理產品有望加速放量,為公司業績增長奠定堅實基礎。公司持續增強源頭創新動能,聚焦前沿技術,開展科研攻關。截至目前, 公司自主研發項目共計30項(不含新冠系列項目),處於臨牀試驗及申請註冊階段的項目17項,其中公司23價肺炎球菌多糖疫苗和四價流感病毒裂解疫苗的申請生產註冊已獲受理。公司在研產品管線豐富,未來若順利獲批上市, 將進一步增強公司核心競爭力。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.